- Home
- BEAM vs MANU Comparison
BEAM vs MANU Comparison
Compare BEAM & MANU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MANU
- Stock Information
- Founded
- BEAM 2017
- MANU 1878
- Country
- BEAM United States
- MANU United Kingdom
- Employees
- BEAM N/A
- MANU N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MANU Services-Misc. Amusement & Recreation
- Sector
- BEAM Health Care
- MANU Consumer Discretionary
- Exchange
- BEAM Nasdaq
- MANU Nasdaq
- Market Cap
- BEAM 1.8B
- MANU 2.2B
- IPO Year
- BEAM 2020
- MANU 2012
- Fundamental
- Price
- BEAM $17.00
- MANU $13.90
- Analyst Decision
- BEAM Strong Buy
- MANU Buy
- Analyst Count
- BEAM 11
- MANU 2
- Target Price
- BEAM $50.50
- MANU $20.75
- AVG Volume (30 Days)
- BEAM 3.0M
- MANU 292.3K
- Earning Date
- BEAM 05-06-2025
- MANU 02-19-2025
- Dividend Yield
- BEAM N/A
- MANU N/A
- EPS Growth
- BEAM N/A
- MANU N/A
- EPS
- BEAM N/A
- MANU N/A
- Revenue
- BEAM $63,518,000.00
- MANU $777,029,683.00
- Revenue This Year
- BEAM N/A
- MANU $2.44
- Revenue Next Year
- BEAM $6.32
- MANU $3.82
- P/E Ratio
- BEAM N/A
- MANU N/A
- Revenue Growth
- BEAM N/A
- MANU N/A
- 52 Week Low
- BEAM $13.53
- MANU $12.05
- 52 Week High
- BEAM $35.25
- MANU $18.42
- Technical
- Relative Strength Index (RSI)
- BEAM 40.71
- MANU 54.26
- Support Level
- BEAM $16.04
- MANU $12.05
- Resistance Level
- BEAM $17.94
- MANU $14.12
- Average True Range (ATR)
- BEAM 1.84
- MANU 0.48
- MACD
- BEAM 0.26
- MANU 0.17
- Stochastic Oscillator
- BEAM 44.24
- MANU 89.37
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MANU Manchester United Ltd.
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, and sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which the majority of the revenue is generated including Commercial, Broadcasting, and Matchday.